This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Renal Cell Carcinoma Urothelial cancer
Renal Cell Carcinoma Urothelial cancer
Advanced MelanomaAdjuvant Melanoma
Adjuvant esophageal (EC or GEJC) 1L adenocarcinoma upper GI 1L or 2L esophageal squamous cell carcinoma (ESCC)
Head & Neck
Hodgkin Lymphoma

Renal Cell Carcinoma

THE FIRST AND ONLY DUAL IMMUNOTHERAPY IN 1L aRCC

View indication details

  • OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.
  • OPDIVO in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.
  • OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.
Expert opinion

Pr Gennigens comments
on dual IO in 1L RCC

Poster mentioned in the video has now been published: Motzer et al, Conditional survival & long-term efficacy, Cancer 2022

A library of patient
cases treated with
OPDIVO+YERVOY in 1L RCC

Product information

A short video on
the rationale of combining
OPDIVO and YERVOY
in collaboration with
P. Coulie

Dosing schemes
in aRCC

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

Patient support program
 OPDIVO + YERVOY

A diary for your aRCC patients
treated with OPDIVO + YERVOY

www.immunooncology.be

An educational website
on immunotherapy
for your nurses

For more patient & nurse materials
click here

1L aRCC, first-line advanced renal cell carcinoma irAE(s), immune-related adverse event(s)